利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.033 秒)

    MELAN-A-CARRIER CONJUGATES
    1.
    发明申请
    MELAN-A-CARRIER CONJUGATES 审中-公开
    梅兰运输公司

    公开(公告)号：US20110097417A1

    公开(公告)日：2011-04-28

    申请号：US12463985

    申请日：2009-05-11

    申请人： Martin F. BACHMANN ,  Vania Manolova ,  Edwin Meijerink ,  Karl G. Proba ,  Katrin Schwarz

    发明人： Martin F. BACHMANN ,  Vania Manolova ,  Edwin Meijerink ,  Karl G. Proba ,  Katrin Schwarz

    IPC分类号： A61K9/14 ,  A61K39/12 ,  A61P37/04

    CPC分类号： A61K39/39 ,  A61K2039/5258 ,  A61K2039/55561 ,  A61K2039/6075 ,  A61K2039/62 ,  A61K2039/64 ,  C07K14/005 ,  C07K14/4748 ,  C12N2710/22022 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2760/10022 ,  Y02A50/467

    摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

    摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸，以及衍生自与其连接的MelanA的特定肽。 这样的CpG-VLP比其不含CpG的对应物显着地更具免疫原性，并诱导增强的B和T细胞应答。 与VLP本身的免疫应答相似，对于任何偶联，融合或附着于VLP的MelanA肽类似物的免疫应答也相似地增强。 此外，针对MelanA肽类似物的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

    VLP-antigen conjugates and their uses as vaccines
    3.
    发明授权
    VLP-antigen conjugates and their uses as vaccines 失效
    VLP-抗原缀合物及其作为疫苗的用途

    公开(公告)号：US07959928B2

    公开(公告)日：2011-06-14

    申请号：US11664716

    申请日：2005-10-05

    申请人： Martin F. Bachmann ,  Karl G. Proba ,  Patrik Maurer ,  Edwin Meijerink ,  Katrin Schwarz

    发明人： Martin F. Bachmann ,  Karl G. Proba ,  Patrik Maurer ,  Edwin Meijerink ,  Katrin Schwarz

    IPC分类号： A61K39/00 ,  C12N7/00

    CPC分类号： A61K39/0013 ,  A61K39/0005 ,  A61K39/0006 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/6075 ,  C12N2740/16211 ,  C12N2795/18123

    摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.

    摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含RNA噬菌体的病毒样颗粒（VLP）和至少一种抗原的组合物，其中VLP在宿主中重组产生，并且其中由VLP包含的具有二级结构的宿主RNA的量为 最多20％的具有二级结构的宿主RNA的量最初由VLP组成; 并且其中所述VLP和所述至少一种抗原彼此连接。 本发明还提供了制备本发明组合物的方法。 本发明的组合物可用于生产用于治疗疾病，病症和病症的疫苗。 此外，本发明的组合物特别可用于在降低或消除不想要的T细胞应答的同时在指定的上下文中有效地诱导针对抗原的强抗体应答。

    Melan-A- carrier conjugates
    5.
    发明授权
    Melan-A- carrier conjugates 失效
    黑色素A-载体缀合物

    公开(公告)号：US07537767B2

    公开(公告)日：2009-05-26

    申请号：US10551054

    申请日：2004-03-25

    申请人： Martin F. Bachmann ,  Vania Manolova ,  Edwin Meijerink ,  Karl G. Proba ,  Katrin Schwartz

    发明人： Martin F. Bachmann ,  Vania Manolova ,  Edwin Meijerink ,  Karl G. Proba ,  Katrin Schwartz

    IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/385

    CPC分类号： A61K39/39 ,  A61K2039/5258 ,  A61K2039/55561 ,  A61K2039/6075 ,  A61K2039/62 ,  A61K2039/64 ,  C07K14/005 ,  C07K14/4748 ,  C12N2710/22022 ,  C12N2730/10122 ,  C12N2730/10123 ,  C12N2760/10022 ,  Y02A50/467

    摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpGVLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Thl type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

    摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含VLP的修饰病毒样颗粒（VLP），其可加载免疫刺激物质，特别是含有非甲基化C和G（CpG）的DNA寡核苷酸，以及衍生自与其连接的MelanA的特定肽。 这样的CpGVLP比其不含CpG的对应物显着地更具免疫原性，并且诱导增强的B和T细胞应答。 与VLP本身的免疫应答相似，对于任何偶联，融合或附着于VLP的MelanA肽类似物的免疫应答也相似地增强。 此外，针对MelanA肽类似物的T细胞应答特别针对Th1型。 因此，连接到CpG负载的VLP的抗原可能是针对过敏，肿瘤和其他自身分子和慢性病毒性疾病的预防性或治疗性接种疫苗的理想疫苗。

    Vlp-Antigen Conjugates and Their Uses as Vaccines
    8.
    发明申请
    Vlp-Antigen Conjugates and Their Uses as Vaccines 失效
    Vlp抗原结合物及其用途作为疫苗

    公开(公告)号：US20080095738A1

    公开(公告)日：2008-04-24

    申请号：US11664716

    申请日：2005-10-05

    申请人： Martin Bachmann ,  Patrik Maurer ,  Edwin Meijerink ,  Katrin Schwarz ,  Karl Proba

    发明人： Martin Bachmann ,  Patrik Maurer ,  Edwin Meijerink ,  Katrin Schwarz ,  Karl Proba

    IPC分类号： A61K39/39 ,  A61K39/00 ,  A61P29/00 ,  A61P37/00 ,  A61K39/385

    CPC分类号： A61K39/0013 ,  A61K39/0005 ,  A61K39/0006 ,  A61K39/0011 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/6075 ,  C12N2740/16211 ,  C12N2795/18123

    摘要： The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising a virus-like particle (VLP) of an RNA-bacteriophage and at least one antigen, wherein the VLP is recombinantly produced in a host, and wherein the amount of host RNA with secondary structure comprised by the VLP is at most 20% of the amount of host RNA with secondary structure originally comprised by the VLP; and wherein the VLP and the at least one antigen are linked with one another. The invention also provides methods for producing the compositions of the invention. The compositions of the invention are useful in the production of vaccines for the treatment of diseases, disorders and conditions. Furthermore, the compositions of the invention are particularly useful to efficiently induce strong antibody responses against the antigen within the indicated context while lowering or eliminating unwanted T cell responses.

    摘要翻译： 本发明涉及分子生物学，病毒学，免疫学和医学领域。 本发明提供了包含RNA噬菌体的病毒样颗粒（VLP）和至少一种抗原的组合物，其中VLP在宿主中重组产生，并且其中由VLP包含的具有二级结构的宿主RNA的量为 最多20％的具有二级结构的宿主RNA的量最初由VLP组成; 并且其中所述VLP和所述至少一种抗原彼此连接。 本发明还提供了制备本发明组合物的方法。 本发明的组合物可用于生产用于治疗疾病，病症和病症的疫苗。 此外，本发明的组合物特别可用于在降低或消除不想要的T细胞应答的同时在指定的上下文中有效地诱导针对抗原的强抗体应答。